Earnings call transcript: Żabka Group Q3 2026 results show growth, slight EPS miss

Żabka Group’s Q3 2026 revenue of $8.46 billion topped the $8.39 billion forecast, while EPS of $0.4374 missed the $0.4524 estimate by 3.32%. Sales to end customers rose 12.3% to 9.6 billion PLN, adjusted EBITDA grew 16.5% to nearly 1.5 billion PLN, and its margin expanded 60 basis points to 15.6%; like-for-like sales increased 3.5% amid subdued food-retail demand. Management remains on track to open more than 1,300 stores in 2026 and expects adjusted EBITDA margin at the top end of its 12%–13% range; shares were little changed, down 0.13% to $31.69.

Analysis

Zabka: growth quality matters more than the headline beat

The key underwriting question is whether margin gains are repeatable while organic demand cools. Store growth can sustain reported sales even if mature-store productivity weakens; it also raises cannibalization and franchisee-return risks. Track cohort paybacks and franchisee economics, not just openings. Scale-driven supplier terms and logistics savings are genuine advantages, but 2027 contract negotiations will test how much pricing power is durable. If concessions reverse, margin expansion could unwind faster than the store base grows.

The EPS shortfall despite stronger operating performance warrants a bridge check: separate recurring operating gains from financing, adjustment and inventory-timing effects before capitalizing the quarter. The reference to higher inventory sold to franchisees makes this especially relevant; it can support reported gross profit without equivalent end-customer demand. Cash conversion is encouraging, but assess it after expansion capex.

Near term, expectations look vulnerable to a softer like-for-like trajectory: management’s full-year confidence leaves little room for a further demand or weather shock. Over 1–3 months, the Q4 comparable-sales outcome, 2027 supplier terms and CEO transition are the key tests. Over 6–18 months, Romania execution and new-store returns matter more than headline openings. The Couche-Tard process is optionality, not an investment case yet; a successful process could alter strategy and capital allocation, while delay or failure removes that catalyst. With the shares already near the upper end of their annual range, strong execution may be needed to extend the rerating.

Key Decisions for Investors

• Do not chase ZAB after the recent rerating. Consider a staged long only on weakness, conditional on full-year like-for-like sales reaching management’s stated 4% expectation and margins holding; upside depends on sustained mature-store productivity, while a miss risks both earnings downgrades and multiple compression.
• For existing longs, keep exposure but make the position conditional: reduce if comparable-sales growth falls short of the full-year goal or if gross-margin gains reverse without offsetting cost efficiencies. Verify the EBITDA-to-EPS bridge and inventory sold to franchisees before treating the quarter’s profit trend as run-rate.
• Monitor 2027 supplier-contract outcomes and new-store cohort returns as the main 1–3 month and 6–18 month signals. Adverse purchasing terms, weaker franchisee economics or rising capex that erodes post-investment cash generation would falsify the operating-leverage thesis.
• Treat the Couche-Tard process as a catalyst watch, not a reason to trade ATD against ZAB: terms, timing and strategic consequences are not established in the supplied information.